Innovative Cellular Therapeutics

Innovative cellular therapies to transform cancer treatment worldwide

Next Generation
CAR-T Technology 

CAR-T cell therapies for blood cancers and solid tumors are being developed by our own significant internal R&D team, based on our comprehensive experience in gene editing, cell therapy and immunotherapy.

Advanced, Clinical Stage CAR-T Platform 

IND cleared by U.S. FDA for ICTCAR014 — IRB-approved human trials in China demonstrated 92.3% ORR (53.8% CR; 38.5% PR), significant tumor shrinkage and limited toxicity. IND cleared by China FDA for ICTCAR003.

for Solid Tumors

IRB-approved human trials being conducted in China with in-house developed CoupledCARTM technology in a range of solid tumor indications.

Better CAR-T Therapy for
Both Liquid and Solid Tumors

Discover our broad pipeline of next generation CAR-T immunotherapies.

ICT has evolved into a fully integrated, international CAR-T biotechnology company with world-class capabilities

Scientific Publications